1  (resulting in p.Val600Glu) in all papillary craniopharyngiomas (3/3, 100%).

2 evealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTN

3 utation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors).

4  in patients with an underlying diagnosis of craniopharyngioma (9.28 [5.84-14.75] vs 1.61 [1.30-1.99]

5 of tumours resembling human adamantinomatous craniopharyngioma (ACP), derived from Sox2- cells in a p

6 of hypopituitarism, hypothalamic obesity, or craniopharyngioma and NAFLD was undertaken.

7 tified age at diagnosis, sex, a diagnosis of craniopharyngioma, and untreated gonadotropin deficiency

8 ents had non-functioning adenomas, 118 (12%) craniopharyngiomas, and 93 (9%) prolactinomas.

9                                              Craniopharyngiomas are epithelial tumors that typically

10 or localized primary brain tumors, including craniopharyngioma, ependymoma, and juvenile pilocytic as

11 beta-catenin) in nearly all adamantinomatous craniopharyngiomas examined (11/12, 92%) and recurrent m

12               Adamantinomatous and papillary craniopharyngiomas harbor mutations that are mutually ex

13 bal attention disorders were associated with craniopharyngioma (P < .0001), supratentorial tumors (P

14            Finally, we reveal that papillary craniopharyngioma (PCP), a benign human pituitary tumour

15          Irradiated primary lesions included craniopharyngioma, pituitary adenoma, Hodgkin's lymphoma

16 igh concentration of proteins (colloid cyst, craniopharyngioma, Rathke's cleft cyst, ectopic posterio

17 Age at diagnosis, female sex, and above all, craniopharyngioma were significant independent risk fact